PediRISE Feasibility

Launched by DANA-FARBER CANCER INSTITUTE · Feb 22, 2024

Keywords

ClinConnect Summary

The PediRISE Feasibility trial is a research study aimed at helping families of children with cancer. The main goal is to see if families are interested in participating in a program called PediRISE, which offers additional support during their child's treatment. Participants will be randomly assigned to one of two groups: one group will receive the PediRISE program, while the other will receive standard care that they would typically get. This study is particularly focused on families facing financial stress and aims to understand how the program can help reduce disparities in care.

To be eligible for this study, children must be under 18 years old, recently diagnosed with cancer, and starting their treatment at one of the participating hospitals. Additionally, families must have a low income and live in Massachusetts, New York, or New Jersey. If you decide to participate, you can expect to be part of a supportive program designed to help you navigate the challenges of cancer treatment. The trial is currently looking for participants, and your involvement could help improve care for future families facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Child diagnosed with de novo cancer
• • Child has established care at a study site and initiated cancer-directed therapy in the prior 2-months
• • Child planned to receive at least 4-months of cancer-directed therapy at study site from time of diagnosis per initial cancer treatment plan
• • Child is \<18 years at time of enrollment
• • Parent/guardian screened positive for self-reported low-income (\<200% FPL).
• • Family primary residence in MA, NY or NJ
• • Provider approval for permission to approach
• Exclusion Criteria:
• • Planned transfer of child to a non-DFCI or non-Columbia facility for cancer-directed therapy
• • Foreign national family receiving care as an Embassy-pay patient
• • Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, AHOD2131, ANBL2131, DFCI 23-001).
• • Child or household member receiving SSI.